Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
17 February 2023 - 8:01AM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced that
it will report financial results for the fourth quarter and full
year 2022 after the market closes on Thursday, February 23,
2023.
Xencor management will host a conference call the same day at
4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and
provide a corporate update.
The live webcast will be available under "Events &
Presentations" in the Investors section of the Company's website
located at investors.xencor.com and will be archived for at least
30 days. Active participants in the conference call may receive
credentials for telephone access by registering at the following
link:
https://register.vevent.com/register/BI70c60751330540e3909534dca3801239.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
proteins structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230216005743/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2023 to Apr 2024